Omni Bio Pharmaceutical Inc (OTCMKTS:OMBP) shares fell 96% during mid-day trading on Friday . The company traded as low as $0.00 and last traded at $0.00, 369,000 shares were traded during mid-day trading. An increase of 391% from the average session volume of 75,100 shares. The stock had previously closed at $0.01.
Omni Bio Pharmaceutical Company Profile (OTCMKTS:OMBP)
Omni Bio Pharmaceutical, Inc operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications.
Read More: Cash Flow
Receive News & Ratings for Omni Bio Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omni Bio Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.